The mechanism is mediated by the combined effect of avidity and a high on and off-rate at each single binding site. Taken together this generates an efficient, selective and also general mode of screening for oligomers. Once the oligomeric form is bound the interaction, as a result of avidity, becomes very strong. Through this mechanism antibody binding to monomers and precursor proteins like APP can be minimized. We also show that oligomer specificity appears to be a general feature of common human anti- Ab IgM autoantibodies. A more extensive analysis comparing the References 1. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45–53. 2. Katzman R (1986) Differential diagnosis of dementing illnesses. Neurol Clin 4: 329–340. 3. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408: 982–985. 4. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173–177. 5. Younkin SG (2001) Amyloid beta vaccination: reduced plaques and improved cognition. Nat Med 7: 18–19. 6. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 5: 452–457. 7. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, et al. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. J Neurosci 22: 6331–6335. 8. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, et al. (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposi- tion by mechanisms both independent of and associated with microglial activation. J Neurosci 23: 3745–3751. 9. Roch JM, Masliah E, Roch-Levecq AC, Sundsmo MP, Otero DA, et al. (1994) Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc Natl Acad Sci U S A 91: 7450–7454. 10. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, et al. (2009) Beta- amyloid monomers are neuroprotective. J Neurosci 29: 10582–10587. 11. Saitoh T, Sundsmo M, Roch JM, Kimura N, Cole G, et al. (1989) Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell 58: 615–622. 12. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100: 23–35. 13. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, et al. (2005) Globular amyloid beta-peptide oligomer - a homogenous and stable neuro- pathological protein in Alzheimer’s disease. J Neurochem 95: 834–847. 14. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486–489. 15. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79: 595–605. 16. Geylis V, Kourilov V, Meiner Z, Nennesmo I, Bogdanovic N, et al. (2005) Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 26: 597–606. 17. Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, et al. (2007) Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer’s disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol 206: 248–256. 18. Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, et al. (2009) Reduced levels of IgM autoantibodies against N- truncated pyroglutamate Abeta in plasma of patients with Alzheimer’s disease. Neurobiol Aging. 19. Szabo P, Relkin N, Weksler ME (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7: 415–420. 20. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, et al. (2008) Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283: 4714–4722. 21. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, et al. (2003) Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer’s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 3: 29–39. 22. Myagkova MA, Gavrilova SI, Lermontova NN, Kalyn YB, Selezneva ND, et al. (2001) Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer’s disease and senile dementia of the Alzheimer type. Bull Exp Biol Med 131: 127–129. Targeting Ab Oligomers oligomer specificity of natural occurring IgM anti-Ab antibodies between groups of healthy donors and AD patients is currently ongoing. Author Contributions Conceived and designed the experiments: MLP KB AO. Performed the experiments: MLP KB MV. Analyzed the data: MLP KB AO. Contributed reagents/materials/analysis tools: MS AO. Wrote the paper: MLP AO. 23. Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, et al. (2009) Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer’s disease. J Neural Transm 116: 913–920. 24. DaSilva KA, Brown ME, McLaurin J (2009) Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer’s DNA vaccine. Vaccine 27: 1365–1376. 25. O’Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421–5426. 26. Myszka DG (1999) Improving biosensor analysis. J Mol Recognit 12: 279–284. 27. Olofsson A, Sauer-Eriksson AE, Ohman A (2009) Amyloid fibril dynamics revealed by combined hydrogen/deuterium exchange and nuclear magnetic resonance. Anal Biochem 385: 374–376. 28. Olofsson A, Lindhagen-Persson M, Sauer-Eriksson AE, Ohman A (2007) Amide solvent protection analysis demonstrates that amyloid-beta(1-40) and amyloid- beta(1-42) form different fibrillar structures under identical conditions. Biochem J 404: 63–70. 29. Hasegawa K, Ono K, Yamada M, Naiki H (2002) Kinetic modeling and determination of reaction constants of Alzheimer’s beta-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry 41: 13489–13498. 30. Chauhan NB, Siegel GJ (2003) Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 74: 142–147. 31. Asami-Odaka A, Obayashi-Adachi Y, Matsumoto Y, Takahashi H, Fukumoto H, et al. (2005) Passive immunization of the Abeta42(43) C- terminal-specific antibody BC05 in a mouse model of Alzheimer’s disease. Neurodegener Dis 2: 36–43. 32. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, et al. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483–6492. 33. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, et al. (1999) Plaque- independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci U S A 96: 3228–3233. 34. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, et al. (2000) High- level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050–4058. 35. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabaya- shi T, et al. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer’s disease. J Neurosci 22: 1858–1867. 36. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, et al. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271: 4077–4081. 37. Shankar GM, Walsh DM (2009) Alzheimer’s disease: synaptic dysfunction and Abeta. Mol Neurodegener 4: 48. 38. Munch G, Robinson SR (2002) Potential neurotoxic inflammatory responses to Abeta vaccination in humans. J Neural Transm 109: 1081–1087. 39. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352–357. 40. Roberts GW, Gentleman SM, Lynch A, Graham DI (1991) beta A4 amyloid protein deposition in brain after head trauma. Lancet 338: 1422–1423. 41. Smith DH, Chen XH, Iwata A, Graham DI (2003) Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg 98: 1072–1077. 42. Raby CA, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, et al. (1998) Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid. J Neurochem 71: 2505–2509. 43. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, et al. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 17: 118–120. 44. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, et al. (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A 100: 6370–6375. 45. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95: 6448–6453. 46. Hartley DM, Zhao C, Speier AC, Woodard GA, Li S, et al. (2008) Transglutaminase induces protofibril-like amyloid beta-protein assemblies that PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13928